EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CDKL3 is a targetable regulator of cell cycle progression in cancers

Haijiao Zhang, Jiahui Lin, Shaoqin Zheng, Lanjing Ma, Zhongqiu Pang, Hongyi Yin, Chengcheng Meng, Yinuo Wang, Qing Han, Xi Zhang, Zexu Li, Liu Cao und 8 weitere

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci178428 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Haijiao Zhang und 19 weiteren Autor:innen. Beteiligte Einrichtung: College of Life and Health Sciences, Northeastern University, Shenyang, China. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Fund for the Central Universities, Liaoning Revitalization Talents Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4HumansAnimalsMiceProtein Serine-Threonine KinasesCyclin-Dependent KinasesCell Line, TumorPhosphorylationProtein Kinase InhibitorsColonic NeoplasmsCell Cycle

Stichwörter der Autor:innen

CancerCell biologyCell cycleDrug therapyTherapeutics

Substanzen

Cyclin-Dependent Kinase 4Protein Serine-Threonine KinasesCyclin-Dependent KinasesCDK4 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • College of Life and Health Sciences, Northeastern University, Shenyang, China.
  • Department of Pathology, the Fourth People's Hospital of Shenyang, Shenyang, China.
  • College of Sciences, Northeastern University, Shenyang, China.
  • College of Basic Medical Science, China Medical University, Shenyang, China.
  • State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.
  • Department of General Surgery, the Fourth Affiliated Hospital, China Medical University, Shenyang, China.

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Fund for the Central Universities
  • Liaoning Revitalization Talents Program
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Zhang, H., Lin, J., Zheng, S., Ma, L., Pang, Z., Yin, H., Meng, C., Wang, Y., Han, Q., Zhang, X., Li, Z., Cao, L., Liu, L., Fei, T., Gao, D., Yang, L., Peng, X., Ding, C., Wang, S., & Sheng, R. (2024). CDKL3 is a targetable regulator of cell cycle progression in cancers. Journal of Clinical Investigation. https://doi.org/10.1172/jci178428

Vancouver

Zhang H, Lin J, Zheng S, Ma L, Pang Z, Yin H, et al. CDKL3 is a targetable regulator of cell cycle progression in cancers. Journal of Clinical Investigation. 2024. doi:10.1172/jci178428

BibTeX
@article{Zhang2024,
  author = {Zhang, Haijiao and Lin, Jiahui and Zheng, Shaoqin and Ma, Lanjing and Pang, Zhongqiu and Yin, Hongyi and Meng, Chengcheng and Wang, Yinuo and Han, Qing and Zhang, Xi and Li, Zexu and Cao, Liu and Liu, Lijun and Fei, Teng and Gao, Daming and Yang, Liang and Peng, Xueqiang and Ding, Chen and Wang, Shixue and Sheng, Ren},
  title = {CDKL3 is a targetable regulator of cell cycle progression in cancers},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci178428}
}
Kostenlos starten →